Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letters to the Editor

Plasma MicroRNAs in Ovarian Cancer—Letter

Haifeng Qiu
Haifeng Qiu
International Peace Maternity and Child Health Hospital of the China Welfare Institute, Shanghai Jiaotong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-13-0561 Published June 2013
  • Article
  • Info & Metrics
  • PDF
Loading

In a recent article, Suryawanshi and colleagues reported that alterations of plasma microRNAs (miRNA or miR) may be novel biomarkers for endometriosis and endometriosis-associated ovarian cancer (1). However, we have some concerns about the findings of this study. It is well known that endometriosis is highly dependent on estrogen levels and that miRNAs are strictly controlled by estrogen (2). In postmenopausal women, sequential changes of miRNAs may occur following the loss of estrogen. After treatment with 10 nmol/L of estrogen (E2) for 24 hours, human endometrial glandular epithelial cells and human leiomyoma smooth muscle cells have a 70% and 50% repression of miR-21, respectively (3, 4), which can be blocked by ICI 182780 (an estrogen inhibitor). A similar phenomenon has also been shown in MCF-7 cells (5). In the Suryawanshi and colleagues study, miR-21 was significantly higher in the endometriosis-associated ovarian cancer and considered to be a specific marker for this cancer, as compared with the 2 groups with normal or upregulated estrogen (normal women and patients with endometriosis). However, patients' ages differed significantly among the group of normal women (average = 38.75 years, with normal estrogen levels), women with endometriosis (average = 36.24 years, with theoretically higher estrogen levels), and patients with endometriosis-associated ovarian cancer (average = 55.36 years, majority with postmenopausal estrogen levels). We hypothesize whether the upregulation of miR-21 could also occur in postmenopausal women without cancer as the result of estrogen deficiency.

Therefore, we propose that a group of age-matched normal women with similar estrogen levels would be the correct choice for a comparison group. In addition, miR-16 and miR-195, 2 other markers identified by Suryawanshi and colleagues, were both suppressed by estrogen in the mouse uterus (6).

Finally, in the animal studies, all 3 markers (miR-21, miR-16, and miR-195) were elevated in endometriosis-associated ovarian cancers, which could be explained by the tumor cells' destruction of normal secretory functions of the ovary. To maximally exclude the interference of estrogen, we believe that a simultaneous contralateral oophorectomy would be appropriate.

In summary, both endometriosis and ovarian cancer are closely related to estrogen levels, and thus, the detection of miRNAs alterations should take estrogen effects into consideration.

See the Response, p. 3326

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • Received February 26, 2013.
  • Revision received March 15, 2013.
  • Accepted March 25, 2013.
  • ©2013 American Association for Cancer Research.

References

  1. 1.↵
    1. Suryawanshi S,
    2. Vlad AM,
    3. Lin HM,
    4. Mantia-Smaldone G,
    5. Laskey R,
    6. Lee M,
    7. et al.
    Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2013;19:1213–24.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Klinge CM
    . miRNAs and estrogen action. Trends Endocrinol Metab 2012;23:223–33.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Pan Q,
    2. Luo X,
    3. Toloubeydokhti T,
    4. Chegini N
    . The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression. Mol Hum Reprod 2007;13:797–806.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Pan Q,
    2. Luo X,
    3. Chegini N
    . Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med 2008;12:227–40.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Wickramasinghe NS,
    2. Manavalan TT,
    3. Dougherty SM,
    4. Riggs KA,
    5. Li Y,
    6. Klinge CM
    . Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. 2009;37:2584–95.
  6. 6.↵
    1. Yamagata K,
    2. Fujiyama S,
    3. Ito S,
    4. Ueda T,
    5. Murata T,
    6. Naitou M,
    7. et al.
    Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol Cell 2009;36:340–7.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Clinical Cancer Research: 19 (12)
June 2013
Volume 19, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Plasma MicroRNAs in Ovarian Cancer—Letter
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Plasma MicroRNAs in Ovarian Cancer—Letter
Haifeng Qiu
Clin Cancer Res June 15 2013 (19) (12) 3325; DOI: 10.1158/1078-0432.CCR-13-0561

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Plasma MicroRNAs in Ovarian Cancer—Letter
Haifeng Qiu
Clin Cancer Res June 15 2013 (19) (12) 3325; DOI: 10.1158/1078-0432.CCR-13-0561
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Drug–Radiotherapy Combination Trial Developments—Letter
  • Drug–Radiotherapy Combination Trial Developments—Response
  • 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Letter
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement